StockDuty ← Dashboard Nov 03, 2026 05:59 AM ET
SignalCorporate

Vertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from Crinetics

Vertex's 2026 revenue guidance of $13.15B-$13.25B plus $40M-$50M from Crinetics drives the score.

What happened: Vertex Pharmaceuticals (VRTX) outlined 2026 revenue guidance while adding a contribution from Crinetics, according to its Q3 2026 earnings call. Key numbers: 2026 revenue guidance of $13.15B to $13.25B. Crinetics adds $40M to $50M. Q3 total revenue grew 12% year-on-year. Why it matters: Management described the quarter as one of excellent commercial results and pipeline advancement, with growth balanced across the U.S. and international from CF.
Vertex Pharmaceuticals (VRTX) outlined 2026 revenue guidance while adding a contribution from Crinetics, according to its Q3 2026 earnings call.
Management described the quarter as one of excellent commercial results and pipeline advancement, with growth balanced across the U.S. and international from CF.
Sources